2024 HCPCS Code Q0221
Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), 600 mg
TAGS: vaccine tixagevimab certain history vaccination weighing severely moderate prophylaxis compromised recommended individuals systems adverse known pediatric older years reaction severe immune either least available
Short Description | Tixagev and cilgav, 600mg |
HCPCS Coverage Code | C - Carrier judgment |
HCPCS Action Code | N - No maintenance for this code |
HCPCS Action Effective Date | February 24, 2022 |
HCPCS Code Added Date | February 24, 2022 |
HCPCS Pricing Indicator Code | 54 - Vaccinations |
HCPCS Multiple Pricing Indicator Code | A - Not applicable as HCPCS priced under one methodology |
HCPCS Coverage Issues Manual Reference Section Number | |
HCPCS Type Of Service Code | V - Pneumococcal/flu vaccine (eff 01/96), Pneumococcal/flu/hepatitis B vaccine (eff 04/95-12/95), Pneumococcal only before 04/95 |
HCPCS Anesthesia Base Unit Quantity | 0 |
Check Similar HCPCS Codes
- Q5116 - Inj., trazimera, 10 mg
- Q5117 - Inj., kanjinti, 10 mg
- Q5118 - Inj., zirabev, 10 mg
- Q5119 - Inj ruxience, 10 mg
- Q5120 - Inj pegfilgrastim-bmez 0.5mg
- Q5121 - Inj. avsola, 10 mg
- Q5122 - Inj, nyvepria
- Q5123 - Inj. riabni, 10 mg
- Q5124 - Inj. byooviz, 0.1 mg
- Q5125 - Inj, releuko 1 mcg
- Q5126 - Inj alymsys 10 mg
- Q5127 - Inj, stimufend, 0.5 mg
- Q5128 - Inj, cimerli, 0.1 mg
- Q5129 - Inj, vegzelma, 10 mg
- Q5130 - Inj, fylnetra, 0.5 mg
- Q5131 - Inj, idacio, 20 mg
- Q5132 - Inj, abrilada, 10 mg
- Q5133 - Inj, tofidence, 1 mg
- Q5134 - Inj, tyruko, 1 mg
- Q5137 - Inj, wezlana, sub cu, 1 mg